Clinical case of locally advanced renal cell carcinoma with an inferior vena cava tumor thrombus treated with VEGFR-TKI/IO combination pembrolizumab + lenvatinib
R. V. Orlova,
M. I. Shkolnik,
M. I. Gluzman,
O. A. Bogomolov,
A. V. Kozlov,
S. A. Sidorova,
I. O. Rutkin https://doi.org/10.17650/1726-9776-2025-21-1-92-99
Abstract
The article presents a clinical case of treatment of a young man with locally advanced renal cell carcinoma with an inferior vena cava tumor thrombus above the diaphragm. Due to non-standard neoadjuvant approach of using modern tyrosine kinase inhibitors of VEGFR and immunotherapy (VEGFR-TKI/IO) combination pembrolizumab + lenvatinib, thoracotomy was avoided and complete pathological regression of the tumor was achieved. Various studies on neoadjuvant therapy of kidney cancer including in patients with tumor thrombus are discussed, and the prospects for introducing this approach into clinical practice are described.
Supporting agencies: The work was performed without external funding
About the Authors
R. V. Orlova
City Clinical Oncological Dispensary; Saint Petersburg State University
Russian Federation
Competing Interests:
Russian Federation
56 Veteranov Prospekt, Saint Petersburg 198255; 7–9 Universitetskaya Naberezhnaya, Saint Petersburg 199034
Competing Interests:
The authors declare no conflict of interest
M. I. Shkolnik
A.M. Granov Russian Scientific Center of Radiology and Surgical Technologies, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
70 Leningradskaya St., Pesochnyy, Saint Petersburg 197758
Competing Interests:
The authors declare no conflict of interest
M. I. Gluzman
City Clinical Oncological Dispensary; Saint Petersburg State University
Russian Federation
Competing Interests:
Russian Federation
Mark Igorevich Gluzman
56 Veteranov Prospekt, Saint Petersburg 198255; 7–9 Universitetskaya Naberezhnaya, Saint Petersburg 199034
Competing Interests:
The authors declare no conflict of interest
O. A. Bogomolov
A.M. Granov Russian Scientific Center of Radiology and Surgical Technologies, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
70 Leningradskaya St., Pesochnyy, Saint Petersburg 197758
Competing Interests:
The authors declare no conflict of interest
A. V. Kozlov
A.M. Granov Russian Scientific Center of Radiology and Surgical Technologies, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
70 Leningradskaya St., Pesochnyy, Saint Petersburg 197758
Competing Interests:
The authors declare no conflict of interest
S. A. Sidorova
A.M. Granov Russian Scientific Center of Radiology and Surgical Technologies, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
70 Leningradskaya St., Pesochnyy, Saint Petersburg 197758
Competing Interests:
The authors declare no conflict of interest
I. O. Rutkin
A.M. Granov Russian Scientific Center of Radiology and Surgical Technologies, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
70 Leningradskaya St., Pesochnyy, Saint Petersburg 197758
Competing Interests:
The authors declare no conflict of interest
References
1. Ferlay J., Ervik M., Lam F. et al. Global Cancer Observatory: Cancer Today (version 1.1). 2024. Available at: https://gco.iarc.fr/today/en/dataviz/bars?mode=cancer&group_populations=1&key=total&types=0_1&sort_by=value1 (accessed 03.02.2025).
2. Malignant tumors in Russia in 2023 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2024. 276 p. (In Russ.).
3. Tabbara M.M., González J., Martucci M., Ciancio G. Current approaches in surgical and immunotherapy-based management of renal cell carcinoma with tumor thrombus. Biomedicines 2023;11(1):204. DOI: 10.3390/biomedicines11010204
4. Kaptein F.H.J., van der Hulle T., Braken S.J.E. et al. Prevalence, treatment, and prognosis of tumor thrombi in renal cell carcinoma. JACC CardioOncology 2022;4:522–31. DOI: 10.1016/j.jaccao.2022.07.011
5. Leibovich B.C., Lohse C.M., Cheville J.C. et al. Renal cell carcinoma with inferior vena cava extension: can classification be optimized to predict perioperative outcomes? Kidney Cancer 2020;4(2):111–5. DOI: 10.3233/KCA-190070
6. Reese A.C., Whitson J.M., Meng M.V. Natural history of untreated renal cell carcinoma with venous tumor thrombus. Urol Oncol 2013;31(7):1305–9. DOI: 10.1016/j.urolonc.2011.12.006
7. Renal parenchyma cancer. Clinical guidelines. Ministry of Health of Russia, 2023. Available at: https://cr.minzdrav.gov.ru/recomend/10_4 (In Russ.).
8. Volkova M.I., Nosov D.A., Alekseev B.Ya. et al. Renal cell carcinoma. RUSSCO practical guidelines, part 1.2. Zlokachestvennye opukholi = Malignant Tumors 2024;14(3s2):207–20. (In Russ.).
9. National Comprehensive Cancer Network. Kidney Cancer (Version 3.2025). Available at: http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf (accessed February 4, 2025).
10. Motzer R., Alekseev B., Rha S.Y. et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 2021;384(14):1289–300. DOI: 10.1056/NEJMoa2035716
11. Marandino L., Campi R., Amparore D. Neoadjuvant and adjuvant immune-based approach for renal cell carcinoma: pros, cons, and future directions. Eur Urol Oncol 2024:S2588-9311(24)00211-6. DOI: 10.1016/j.euo.2024.09.002
12. Bex A., Abu-Ghanem Y., Thienen J.V.V. et al. Efficacy, safety, and biomarker analysis of neoadjuvant avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx). J Clin Oncol 2022;40(Suppl. S6):289.
13. Karam J.A., Msaouel P., Haymaker C.L. et al. Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma. Nat Commun 2023;14(1):2684. DOI: 10.1038/s41467-023-38342-7
14. Huang J., Wang Y., Xu F. et al. Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial. J Immunother Cancer 2024;12:e008475. DOI: 10.1136/jitc-2023-008475
15. Zhang S., Ji C., Liu G., Guo H. A phase II study of neoadjuvant tislelizumab and axitinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma (accRCC). J Clin Oncol 2024;42(Suppl. S4):420.
16. Qin Q., Tachibana I., Margulis V. et al. A review of neoadjuvant therapy for localized and locally advanced renal cell carcinoma. Cancers 2025;17(2):312. DOI: 10.3390/cancers17020312
Review
For citations:
Orlova R.V., Shkolnik M.I., Gluzman M.I., Bogomolov O.A., Kozlov A.V., Sidorova S.A., Rutkin I.O. Clinical case of locally advanced renal cell carcinoma with an inferior vena cava tumor thrombus treated with VEGFR-TKI/IO combination pembrolizumab + lenvatinib. Cancer Urology. 2025;21(1):92-99. (In Russ.) https://doi.org/10.17650/1726-9776-2025-21-1-92-99
Views:
129
Email this article 